<p>低市值生物科技公司是一種高風險但高回報的投資選擇。如果它們的臨牀試驗取得成功，這往往意味着價值會激增，因為投資者預期會有收購。</p>
<p>然而，如果它們失敗，這可能意味着這些公司的終結。以下是一份定價低於 10 美元的有潛力的生物科技公司名單，它們可能在未來幾個月內提供巨大的投資回報。</p>
<h2>Actinium Pharmaceuticals (ATNM)</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Shutterstock</p>
<p><strong>Actinium Pharmaceuticals</strong>（NYSEMKT：<strong>ATNM</strong>）是一家生物科技公司，致力於為失敗現有治療的癌症患者提供靶向放射治療。</p>
<p>其當前產品管線是針對處於第 3 期臨牀試驗中的產品。這些產品針對老年人，患有活動性複發性或難治性急性髓樣白血病。</p>
<p>華爾街分析師對這家處於臨牀階段的生物科技公司非常樂觀。他們給出了平均價格目標為 25.60 美元，根據最近約 7 美元的股價，意味着上漲了 267.82%。最樂觀的分析師預測股價將達到 50 美元，上漲潛力為 618.39%。</p>
<p>對於 2024 財年，分析師預測每股虧損 1.73 美元。這是與去年每股 1.83 美元的虧損相比的重大改善。雖然預計 Actinium 在 2024 年不會產生實質性銷售額，但分析師預測如果其臨牀階段試驗成功，到 2025 年將會有鉅額銷售額。這使其成為生物科技行業最具吸引力的低於 10 美元的股票之一。</p>
<h2>Iovance Biotherapeutics (IOVA)</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Gorodenkoff / Shutterstock.com</p>
<p><strong>Iovance Biotherapeutics</strong>（NASDAQ：<strong>IOVA</strong>）致力於開發創新的癌症治療，涉及腫瘤浸潤性白細胞的發展。這些細胞會殺死體內的有缺陷細胞。然而，它們有時需要幫助才能正確執行其職責。</p>
<p>該公司已獲得一種名為 Amtagvi 的批准療法，該療法於 2 月獲得 FDA 批准。目前僅批准用於一部分黑色素瘤患者。然而，Iovance 還有其他五項臨牀試驗可與該治療一起使用。它在各種研究階段中有一長串治療方案。</p>
<p>在 2023 年初，該公司獲得了 Proleukin 的權利，這是一種已獲 FDA 批准的白細胞介素-2 產品。除了有助於促進收入增長外，新獲得的藥物在與 Amtagvi 聯合使用時促進了更好的反應。</p>
<p>在其 2024 財年第一季度業績中，Iovance Biotherapeutics 報告稱已有 100 多名患者接受了使用 Amtagvi 的治療方案。該公司還預計將獲得在歐盟、英國和加拿大使用該藥物的批准。</p>
<p>已經上市兩種藥物並且有更多臨牀試驗在進行中，IOVA 股票可能會在未來幾個月內價值激增。分析師對其未來持樂觀態度。他們預測每股平均價格目標為 25.58 美元，根據最近 7.28 美元的股價，上漲了 230.92%。在預測的最高端，最樂觀的分析師預計每股 34 美元，上漲 339.84%。</p>
<h2>Geron (GERN)</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：shutterstock.com/Romix Image</p>
<p><strong>Geron</strong>（NASDAQ：<strong>GERN</strong>）是一家臨牀生物製藥公司，致力於開發和商業化血液癌症治療。其主要產品是處於第 3 期臨牀試驗中的端粒酶抑制劑。它抑制了血液中的癌細胞的進展。</p>
<p>6 月，Geron 宣佈獲得 Rytelo（Imetelstat）在患有輸血依賴性貧血的低風險骨髓增生異常綜合徵（MDS）患者中使用的批准。</p>
<p>根據其 2024 財年第一季度業績，該公司擁有 4.65 億美元的流動性，為其提供了充足的空間來操作和支持現有試驗。與 2023 年第一季度的 21,000 美元相比，其收入也大幅增長至 304,000 美元。</p>
<p>該公司還預測，它仍有足夠的資源支持運營，直到 2026 年第二季度。在 Imetelstat 獲得在美國使用批准後，該公司可能會改善其第二季度的收入前景。</p>
<p>Imetelstat 是 <strong>Merck</strong>（NYSE：<strong>MRK</strong>）和 <strong>Bristol-Myers Squibb</strong>（NYSE：<strong>BMY</strong>）產品的直接競爭對手。這使得 Geron 成為被收購的主要候選公司。鑑於腫瘤學的併購活動在醫療保健領域非常流行，GERN 投資者在收購時可能會看到股價大幅提升。分析師對 GERN 持樂觀態度。他們給予該股票平均價格目標為 6.81 美元，根據最近 4.53 美元的股價，上漲了 63.31%。在預測的最高端，分析師預測 10 美元，上漲了 139.81%。</p>
<p><em>在發佈日期，Joel Lim 在本文提到的證券中沒有（直接或間接）任何頭寸。本文中表達的觀點屬於作者本人，遵守 InvestorPlace.com 的發佈準則。</em></p>
<p><em>在發佈日期，負責編輯在本文提到的證券中沒有（直接或間接）任何頭寸。</em></p>
<p>Joel Lim 是 InvestorPlace.com 的撰稿人，也是一名金融內容承包商，為 LTSE 和 Realtor 等多家公司以及 Business Insider、Yahoo Finance、Mises Institution 和 Foundation for Economic Education 等金融出版物創作內容。</p>
<p>醫療保健、生物科技</p>
<p>成長股、低估股票</p>

傑龍公司

<p>被定價低於 10 美元的小市值生物科技公司被視為高風險但高回報的投資選擇。Actinium Pharmaceuticals（ATNM）、Iovance Biotherapeutics（IOVA）和 Geron（GERN）被提及為有潛力獲得顯著回報的有前景的生物科技公司。這些公司正在開發創新的癌症治療方法，並且其產品正在進行第三階段臨牀試驗。分析師對它們的未來持樂觀態度，預期有價格目標和潛在的收購機會</p>

<p>Low-cap biotech companies are a high-risk but high-reward investment choice. If their clinical trials are successful, that can often mean an explosion in value as investors anticipate a buyout.</p>
<div class="lb-trans"><p>低市值生物科技公司是一種高風險但高回報的投資選擇。如果它們的臨牀試驗取得成功，這往往意味着價值會激增，因為投資者預期會有收購。</p>
</div><p>However, if they fail, that may mean the end of the road for these companies. Here is a list of promising biotechs priced under $10 that could offer a huge return on investment in the coming months.</p>
<div class="lb-trans"><p>然而，如果它們失敗，這可能意味着這些公司的終結。以下是一份定價低於 10 美元的有潛力的生物科技公司名單，它們可能在未來幾個月內提供巨大的投資回報。</p>
</div><h2>Actinium Pharmaceuticals (ATNM)</h2>
<div class="lb-trans"><h2>Actinium Pharmaceuticals (ATNM)</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>來源：Shutterstock</p>
</div><p><strong>Actinium Pharmaceuticals</strong> (NYSEMKT: <strong>ATNM</strong>) is a biotech working on target radiotherapy treatment for cancer patients who failed existing treatments.</p>
<div class="lb-trans"><p><strong>Actinium Pharmaceuticals</strong>（NYSEMKT：<strong>ATNM</strong>）是一家生物科技公司，致力於為失敗現有治療的癌症患者提供靶向放射治療。</p>
</div><p>Its current product pipeline is for products that are in Phase 3 clinical trials. These are targeted at the elderly with active relapsed or refractory acute myeloid leukemia.</p>
<div class="lb-trans"><p>其當前產品管線是針對處於第 3 期臨牀試驗中的產品。這些產品針對老年人，患有活動性複發性或難治性急性髓樣白血病。</p>
</div><p>Wall Street analysts are quite optimistic about this clinical-stage biotech. They give it an average price target of $25.60, implying 267.82% upside based on the most recent price of around $7 per share. The most optimistic analysts forecast a price of $50, or 618.39% upside potential.</p>
<div class="lb-trans"><p>華爾街分析師對這家處於臨牀階段的生物科技公司非常樂觀。他們給出了平均價格目標為 25.60 美元，根據最近約 7 美元的股價，意味着上漲了 267.82%。最樂觀的分析師預測股價將達到 50 美元，上漲潛力為 618.39%。</p>
</div><p>For fiscal 2024, the analysts forecast a loss per share of $1.73. That is a major improvement from last year’s $1.83 loss per share. While Actinium is not expected to generate meaningful sales in 2024, analysts forecast huge sales in 2025 if its clinical stage trial succeeds. That makes it amongst the biotech industry’s most lucrative under $10 stocks.</p>
<div class="lb-trans"><p>對於 2024 財年，分析師預測每股虧損 1.73 美元。這是與去年每股 1.83 美元的虧損相比的重大改善。雖然預計 Actinium 在 2024 年不會產生實質性銷售額，但分析師預測如果其臨牀階段試驗成功，到 2025 年將會有鉅額銷售額。這使其成為生物科技行業最具吸引力的低於 10 美元的股票之一。</p>
</div><h2>Iovance Biotherapeutics (IOVA)</h2>
<div class="lb-trans"><h2>Iovance Biotherapeutics (IOVA)</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Gorodenkoff / Shutterstock.com</p>
<div class="lb-trans"><p>來源：Gorodenkoff / Shutterstock.com</p>
</div><p><strong>Iovance Biotherapeutics</strong> (NASDAQ: <strong>IOVA</strong>) is working on innovative cancer treatments that entail the development of tumor-infiltrating white blood cells. These cells kill faulty cells in the body. However, they sometimes need help figuring out how to perform their duties correctly.</p>
<div class="lb-trans"><p><strong>Iovance Biotherapeutics</strong>（NASDAQ：<strong>IOVA</strong>）致力於開發創新的癌症治療，涉及腫瘤浸潤性白細胞的發展。這些細胞會殺死體內的有缺陷細胞。然而，它們有時需要幫助才能正確執行其職責。</p>
</div><p>It has one approved therapy called Amtagvi, which received FDA approval in February. It is currently only approved for a subset of melanoma patients. However, Iovance has five other clinical trials for use with this treatment. It has a long list of treatments in various phases of study.</p>
<div class="lb-trans"><p>該公司已獲得一種名為 Amtagvi 的批准療法，該療法於 2 月獲得 FDA 批准。目前僅批准用於一部分黑色素瘤患者。然而，Iovance 還有其他五項臨牀試驗可與該治療一起使用。它在各種研究階段中有一長串治療方案。</p>
</div><p>In early 2023, the company acquired rights to Proleukin, an interleukin-2 product that has received FDA approval. Besides helping promote revenue growth, the newly acquired drug promotes a better response when combined with Amtagvi.</p>
<div class="lb-trans"><p>在 2023 年初，該公司獲得了 Proleukin 的權利，這是一種已獲 FDA 批准的白細胞介素-2 產品。除了有助於促進收入增長外，新獲得的藥物在與 Amtagvi 聯合使用時促進了更好的反應。</p>
</div><p>In its first quarter fiscal 2024 results, Iovance Biotherapeutics reported over 100 patients were enrolled into a treatment regime using Amtagvi. The company also expects to receive approval for the use of the drug in the EU, U.K., and Canada.</p>
<div class="lb-trans"><p>在其 2024 財年第一季度業績中，Iovance Biotherapeutics 報告稱已有 100 多名患者接受了使用 Amtagvi 的治療方案。該公司還預計將獲得在歐盟、英國和加拿大使用該藥物的批准。</p>
</div><p>With two drugs already on the market and more clinical trials in the pipeline, IOVA shares could see an explosion in value in the coming months. Analysts are optimistic about its future. They forecast an average price target of $25.58 per share, a 230.92% upside based on the most recent price of $7.28. On the upper end of the forecast, the most optimistic analysts expect $34 per share, which is a 339.84% upside.</p>
<div class="lb-trans"><p>已經上市兩種藥物並且有更多臨牀試驗在進行中，IOVA 股票可能會在未來幾個月內價值激增。分析師對其未來持樂觀態度。他們預測每股平均價格目標為 25.58 美元，根據最近 7.28 美元的股價，上漲了 230.92%。在預測的最高端，最樂觀的分析師預計每股 34 美元，上漲 339.84%。</p>
</div><h2>Geron (GERN)</h2>
<div class="lb-trans"><h2>Geron (GERN)</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: shutterstock.com/Romix Image</p>
<div class="lb-trans"><p>來源：shutterstock.com/Romix Image</p>
</div><p><strong>Geron</strong>(NASDAQ: <strong>GERN</strong>) is a clinical biopharmaceutical company developing and commercializing blood cancer treatments. Its primary product, which is in Phase 3 clinical trials, is a telomerase inhibitor. It inhibits the progression of cancer cells in the blood.</p>
<div class="lb-trans"><p><strong>Geron</strong>（NASDAQ：<strong>GERN</strong>）是一家臨牀生物製藥公司，致力於開發和商業化血液癌症治療。其主要產品是處於第 3 期臨牀試驗中的端粒酶抑制劑。它抑制了血液中的癌細胞的進展。</p>
</div><p>In June, Geron announced the approval of Rytelo (Imetelstat) for use in patients with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia.</p>
<div class="lb-trans"><p>6 月，Geron 宣佈獲得 Rytelo（Imetelstat）在患有輸血依賴性貧血的低風險骨髓增生異常綜合徵（MDS）患者中使用的批准。</p>
</div><p>According to its fiscal first quarter results, the company has $465 million in liquidity, giving it plenty of space to maneuver and support existing trials. It also grew revenue significantly to $304,000 compared to $21,000 in the first quarter of 2023.</p>
<div class="lb-trans"><p>根據其 2024 財年第一季度業績，該公司擁有 4.65 億美元的流動性，為其提供了充足的空間來操作和支持現有試驗。與 2023 年第一季度的 21,000 美元相比，其收入也大幅增長至 304,000 美元。</p>
</div><p>The company also forecasts that it still has enough resources to support operations until the second quarter of 2026. Following the approval of Imetelstat for use in the U.S., it is likely the company will improve its revenue outlook in Q2.</p>
<div class="lb-trans"><p>該公司還預測，它仍有足夠的資源支持運營，直到 2026 年第二季度。在 Imetelstat 獲得在美國使用批准後，該公司可能會改善其第二季度的收入前景。</p>
</div><p>Imetelstat is a direct competitor to <strong>Merck</strong> (NYSE: <strong>MRK</strong>) and <strong>Bristol-Myers Squibb</strong> (NYSE: <strong>BMY</strong>) products. That makes Geron a prime candidate for a buyout. Given that oncology merger and acquisition activity is quite popular in the healthcare space, GERN investors could see a huge boost in share price in case of a buyout. Analysts are quite optimistic about GERN. They give the stock an average price target of $6.81, a 63.31% upside based on the most recent price of $4.53 per share. At the high end of the forecast, analysts forecast $10, a 139.81% upside.</p>
<div class="lb-trans"><p>Imetelstat 是 <strong>Merck</strong>（NYSE：<strong>MRK</strong>）和 <strong>Bristol-Myers Squibb</strong>（NYSE：<strong>BMY</strong>）產品的直接競爭對手。這使得 Geron 成為被收購的主要候選公司。鑑於腫瘤學的併購活動在醫療保健領域非常流行，GERN 投資者在收購時可能會看到股價大幅提升。分析師對 GERN 持樂觀態度。他們給予該股票平均價格目標為 6.81 美元，根據最近 4.53 美元的股價，上漲了 63.31%。在預測的最高端，分析師預測 10 美元，上漲了 139.81%。</p>
</div><p><em>On the date of publication, Joel Lim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>
<div class="lb-trans"><p><em>在發佈日期，Joel Lim 在本文提到的證券中沒有（直接或間接）任何頭寸。本文中表達的觀點屬於作者本人，遵守 InvestorPlace.com 的發佈準則。</em></p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在發佈日期，負責編輯在本文提到的證券中沒有（直接或間接）任何頭寸。</em></p>
</div><p>Joel Lim is a contributor at InvestorPlace.com and a finance content contractor who creates content for several companies like LTSE and Realtor, along with financial publications, including Business Insider, Yahoo Finance, Mises Institution and Foundation for Economic Education.</p>
<div class="lb-trans"><p>Joel Lim 是 InvestorPlace.com 的撰稿人，也是一名金融內容承包商，為 LTSE 和 Realtor 等多家公司以及 Business Insider、Yahoo Finance、Mises Institution 和 Foundation for Economic Education 等金融出版物創作內容。</p>
</div><p>Healthcare, Biotech</p>
<div class="lb-trans"><p>醫療保健、生物科技</p>
</div><p>Growth Stocks, Undervalued Stocks</p>
<div class="lb-trans"><p>成長股、低估股票</p>
</div>

3 只價格低於 10 美元的生物科技股票可能讓你致富